<code id='27EBF42475'></code><style id='27EBF42475'></style>
    • <acronym id='27EBF42475'></acronym>
      <center id='27EBF42475'><center id='27EBF42475'><tfoot id='27EBF42475'></tfoot></center><abbr id='27EBF42475'><dir id='27EBF42475'><tfoot id='27EBF42475'></tfoot><noframes id='27EBF42475'>

    • <optgroup id='27EBF42475'><strike id='27EBF42475'><sup id='27EBF42475'></sup></strike><code id='27EBF42475'></code></optgroup>
        1. <b id='27EBF42475'><label id='27EBF42475'><select id='27EBF42475'><dt id='27EBF42475'><span id='27EBF42475'></span></dt></select></label></b><u id='27EBF42475'></u>
          <i id='27EBF42475'><strike id='27EBF42475'><tt id='27EBF42475'><pre id='27EBF42475'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:256
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          3 questions for the future of Biden's cancer moonshot
          3 questions for the future of Biden's cancer moonshot

          PresidentJoeBidenEliseAmendola/APWASHINGTON—ThelatestphaseofPresidentBiden’sCancerMoonshotinitiative

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Eli Lilly buys Point Biopharma in radiopharmaceuticals play

          DarronCummings/APAcouplebillionhere,acouplebillionthere,andprettysoonEliLillyhopesitwillbetalkingabo